[cs_content][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 20px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 10px 0px 0px;”][x_image type=”none” src=”http://beatcc2018.wpengine.com/wp-content/uploads/2017/06/erizhejorvhgozfjempk.jpg” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][x_image type=”none” src=”http://beatcc2018.wpengine.com/wp-content/uploads/2017/04/conneticut-childrens.png” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][x_line style=”border-top-width: 1px;”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”2/3″ style=”padding: 0px;”][cs_text class=”cs-ta-left”]

Dr. Michael Isakoff

Connecticut Children’s Medical Center

[/cs_text][cs_text]Dr. Isakoff is the site Principal Investigator of Beat Childhood Cancer (formerly NMTRC) at Connecticut Children’s, the Clinical Director of the Center for Cancer and Blood Disorders, and Medical Director of the Clinical Trials Unit at Connecticut Children’s.

Appointments: (860)-545-9630 to schedule.

282 Washington Street
Hartford, CT 06106
Phone: (860) 545-9630

E-mail: misakoff@connecticutchildrens.org[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 45px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_tab_nav type=”three-up” float=”top”][x_tab_nav_item title=”Background” active=”true”][x_tab_nav_item title=”Education” active=”true”][x_tab_nav_item title=”Selected Publications” active=”false”][/x_tab_nav][x_tabs][x_tab active=”true”]Dr. Isakoff is a Pediatric Oncologist and is the Clinical Director of the Center for Cancer and Blood Disorders at Connecticut Children’s Medical Center in Hartford, CT.

Dr. Isakoff is an Associate Professor at the Uconn School of Medicine. His research interests include clinical trial development for children, adolescent, and young adults with refractory cancers. As the site principal investigator for Beat Childhood Cancer (formerly NMTRC) Dr. Isakoff and the clinical trials team at CT Children’s has successfully opened new Phase I and II trials for patients with a variety of cancer diagnoses, including Molecular Guided Therapy trials using precision medicine based on genomic analysis of pediatric tumors. Beat Childhood Cancer is a collaborative team of over 40 distinguished universities and children’s hospitals that have joined together to offer a national network of clinical trials. Through the collaboration with Beat Childhood Cancer, Dr. Isakoff hopes to provide world class cutting edge therapies to patients close to home. [/x_tab][x_tab active=”true”]

 [/x_tab][x_tab active=”false”]Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E, Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med. 2016 Feb;5(2):294-303. doi:10.1002/cam4.598. Epub 2015 Dec 29. PubMed PMID: 26714427; PubMed Central PMCID:PMC4735769.

Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Gorlick R, Doski JJ, Womer RB, Janeway KA. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children’s Oncology Group. Pediatr Blood Cancer. 2016 Feb;63(2):370-1. doi:10.1002/pbc.25754. Epub 2015 Sep 16. PubMed PMID: 26376351.

Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of Clinical Oncology. August 24, 2015. 10.1200/JCO.2014.59.4895.[Epub ahead of print]

Wong T, Goldsby RE, Wustrack R, Cash T, Isakoff MS, DuBois SG. Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. Pediatr Blood Cancer. 2015 Jul 14. doi: 10.1002/pbc.25635. [Epub ahead of print]

Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.. Pediatr Blood Cancer. 2014 Apr;61(4):636-42. doi: 10.1002/pbc.24794. Epub 2013 Oct 4.

Isakoff MS, Freyer DR, and Bleyer A, Young adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen do not need a bone marrow transplant in first remission. Blood 2013 121:5253-5255
[/x_tab][/x_tabs][/cs_column][/cs_row][/cs_section][/cs_content]